SERUM NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) AS A PREDICTIVE BIOMARKER OF KIDNEY INJURY IN RENAL TRANSPLANTED PATIENTS and CHRONIC KIDNEY DISEASE

Authors

  • Zainab A.a. Al-shamma Baghdad College of Pharmacy. Baghdad, Iraq.
  • Nahla Ghanim Alklyali Ministry of health. Baghdad. Iraq
  • Intesar Yousif Alani Medical city, Ministry of health. Baghdad. Iraq

DOI:

https://doi.org/10.22159/ijpps.2017v9i6.17510

Keywords:

Neutrophil gelatinase-associated lipocalin, Kidney injury, Kidney transplant recipients, Chronic kidney disease

Abstract

Objective: Neutrophil gelatinase-associated lipocalin has emerged as a promising biomarker of kidney injury better than creatinine to early predict the acute kidney injury in both chronic kidney diseases and early diagnosis of kidney allograft dysfunction.

Methods: Neutrophil gelatinase-associated lipocalin was evaluated as a new biomarker for acute renal injury in 69 patients were divided in two groups chronic kidney disease patients (stage5), (n=34), and renal transplant patients, (n=35) comparing with apparently healthy control (n= 35) of matching age and weight. Neutrophil gelatinase-associated lipocalin, hsCRP and Cystatin-C were measured by enzyme-linked immune sorbent assay which is included first incubating the test serum in an antigen-coated polystyrene plate, then enzyme labelled anti-immunoglobulin is added and the enzyme then remaining in plate after washing provides a measure of the amount of specific antibody in the serum and in the final step a substance is added that the enzyme can convert to some detectable signal, most commonly a color change in a chemical substrate.

Results: There was a significant increase in serum NGAL of renal transplantation patients, and CKD patients (stage5) than in healthy control subjects (455±145 ng/ml vs. 296.4±83.5 ng/ml 486±153 ng/ml vs296. 4±83.5 ng/ml) respectively. A high serum Neutrophil gelatinase-associated lipocalin is noted in renal transplanted patients after one month, then after six months (480±188ng/ml vs. 409±78ng/ml). There was a significant negative correlation between serum Neutrophil gelatinase-associated lipocalin in renal transplanted patients, and chronic kidney disease patients (stage 5) with an estimated glomerular filtration rate (p<0.05).

Conclusion: Serum neutrophil gelatinase-associated lipocalin seems to be an early predictor of kidney injury and post-transplantation management, including dialysis and grafting function of the kidney.

Downloads

Download data is not yet available.

Author Biographies

Zainab A.a. Al-shamma, Baghdad College of Pharmacy. Baghdad, Iraq.

Department of Clinical Pharmacy and Therapeutics

Nahla Ghanim Alklyali, Ministry of health. Baghdad. Iraq

Educational laboratories

Intesar Yousif Alani, Medical city, Ministry of health. Baghdad. Iraq

Renal transplant center

References

Dasari P, konuru V, venisetty RK. Management of comorbidities in chronic kidney disease: a prospective observational study. Int J Pharm Pharm Sci 2014;6:363-7.

Devarajan Prasad. Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. Biomarkers Med 2010;4:265–80.

Mårtensson J, Martling CR, Bell MJ. Martensson novel biomarkers of acute kidney injury and failure: clinical applicability. Br J Anaesthesia 2012;109:843–50.

Gillespie A, Lee IJ. Biomarkers in renal transplantation. Biomark Med 2008;2:603–12.

Parikh CR, Moledina DG, Coca SG, Thiessen-Philbrook HR, Garg AX. Application of new acute kidney injury biomarkers in human randomized controlled trials. Kidney Int 2016;89:1372–9.

Malyszko J, Lukaszyk E, Glowinska I, Durlik M. Biomarkers of delayed graft function as a form of acute kidney injury in kidney transplantation. Sci Rep 2015;5:11684.

Xu SY, Carlson M, Engström A, Garcia R, Peterson CG, Venge P. Purification and characterization of a human neutrophil lipocalin (HNL) from the secondary granules of human neutrophils. Scand J Clin Lab Invest 1994;54:365–76.

Flower DR, North AC, Sansom CE. The lipocalin protein family: structural and sequence overview. Biochim Biophys Acta 2000;1482:9–24.

Mori K, Nakao K. Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage. Kidney Int 2007;71:967-70.

Supavekin S, Zhang W, Kucherlapati R, Kaskel FJ, Moore LC, Devarajan Pet. Differential gene expression following early renal ischemia-reperfusion. Kidney Int 2003;63:1714–24.

Mishra J, Ma Q, Prada A, Zahedi K, Yang Y, Barasch J, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel urinary biomarker for ischemic injuryâ€. J Am Soc Nephrol 2003;4:2534–43.

Siedlecki A, Irish W, Brennan DC. Delayed graft function in the kidney transplant. Am J Transplant 2011;11:2279-96.

Akkina SK, Connaire JJ, Israni AK, Snyder JJ, Matas AJ, Kasiske BL. Similar outcomes with different rates of delayed graft function may reflect center practice, not center performance. Am J Transplant 2009;9:1460–6.

Hollmen ME, Kyllönen LE, Inkinen KA, Lalla MLT, Merenmies J, Salmela KT. Deceased donor neutrophil gelatinase-associated lipocalin and delayed graft function after kidney transplantation: a prospective study. Crit Care 2011;15:R121.

Magnusson NE, Hornum M, Jørgensen KA, Hansen JM, Bistrup C, Feldt-Rasmussen B, et al. Plasma neutrophil gelatinase-associated lipocalin (NGAL) is associated with kidney function in uremic patients before and after kidney transplantation. BMC Nephrol 2012;13:8.

Bataille A, Abbas S, Semoun O, Bourgeois É, Marie O, Bonnet F, et al. Plasma neutrophil gelatinase-associated lipocalin in kidney transplantation and early renal function prediction. Transplantation 2011;92:1024–30.

Haase-Fielitz A, Haase M, Devarajan P. Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury: a critical evaluation of current status. Ann Clin Biochem 2014;51:335–51.

Haase M, Haase-Fielitz A. Neutrophil gelatinase-associated lipocalin for acute kidney injury–the renal troponin? J Lab Med 2010;165:28–32.

DiSomma S, Magrini L, De Berardinis B, Marino R, Ferri E, Moscatelli P, et al. Additive value to clinical judgement of blood neutrophil gelatinase-associated lipocalin in diagnosis of acute kidney injury and prediction of mortality in patients hospitalized from the emergency department. Critical Care 2012;16:P354.

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12.

World Health Organization WHO. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. WHO Technical Report Series 894. Geneva; 2000.

Mishra J, Mori K, Ma Q, Kelly C. Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 2004;24:307-15.

Mishra J, Ma Q, Prada A. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003;14:2534-43.

Moise, B Serbænescu, C Gîngu, I Constantinescu. Neutrophil gelatinase-associated lipocalin (NGAL)–a potential biomarker for early diagnosis of acute rejection in renal transplantation. Rev Românæ Urol 2012;11:26-30.

Lebkowska U, Malyszko J, Lebkowska A. Neutrophil gelatinase-associated lipocalin and cystatin C could predict renal outcome in patients undergoing kidney allograft transplantation: a prospective study. Transplant Proc 2009;41:154–7.

Kavalci Cemil, Celikel Elif, Yilmaz Muhittin Serkan. The value of serum NGAL in the determination of dialysis indication 2014;64:739-42.

Parikh CR, Devrajan P. New biomarkers of acute kidney injury. Crit Care Med 2008;36:166-71.

Mahdavi-Mazdeh M, Amerian M, Abdollahi A, Hatmi ZN, Khatami MR. Comparison of serum neutrophil gelatinase-associated lipocalin (NGAL) with serum creatinine in the prediction of kidney recovery after renal transplantation. Int J Organ Transplant Med 2012;3:176–82.

Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of kidney disease. Scand J Clin Lab Invest Suppl 2008;241:89-94.

Ozkan S, Durukan P, Kavalci C, Duman A, Sayhan MB, Salt O, et al. Importance of neutrophil gelatinase-associated lipocalin in the differential diagnosis of acute and chronic renal failure. Iran Red Crescent Med J 2014;16:e14133.

Kümpers P, Hafer C, Lukasz A, Lichtinghagen R, Brand K, Fliser D, et al. Serum neutrophil gelatinase-associated lipocalin at the inception of renal replacement therapy predicts survival in critically ill patients with acute kidney injury. Crit Care 2010;14:R9.

Haase M, Devarajan P, Haase-Fielitz A, Bellomo R, Cruz DN, Wagener G, et al. The outcome of neutrophil gelatinase-associated lipocalin (NGAL)-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J Am Coll Cardiol 2011;57:1752–61.

Sanjeevani S, Pruthi S, Kalra S, Goel A, Kalra OP. Role of neutrophil gelatinase-associated lipocalin for early detection of acute kidney injury. Int J Crit Illness Injury Sci 2014;4:223–8.

Mori K, Lee HT, Rapoport D, Drexler IR, Foster K, Yang J, et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 2005;115:610–21.

Nishida M, Kawakatsu H, Okumura Y, Hamaoka K. Serum and urinary neutrophil gelatinase-associated lipocalin levels in children with chronic renal diseases. Pediatr Int 2010;52:563-8.

Bolignano D, Lacquaniti A, Coppolino G, Donato V, Campo S, Fazio MR, et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 2009;4:337–44.

Esin Avci Çiçek, Simin Rota, Belda Dursun, Emine Kavalci. Evaluation of serum NGAL and hepcidin levels in chronic kidney disease patients. Ren Fail 2016;38:35-9.

Yarlagadda SG, Coca SG, Formica RN Jr, Poggio ED, Parikh CR. Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis. Nephrol Dial Transplant 2009;24:1039-47.

Bolignano D, Coppolino G, Romeo A, Lacquaniti A, Buemi M. Neutrophil gelatinase-associated lipocalin levels in chronic hemodialysis patients. Nephrology 2010;15:23–6.

Mitsnefes MM, Kathman TS, Mishra J, Kartal J, Khoury RP, Thomas L, et al. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney disease. Pediatr Nephrol 2007;22:101-8.

Aghel A, Shrestha K, Mullens W, Borowski A, Tang WH. Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail 2010;16:49-54.

Malyszko J, Bachorzewska-Gajewska H, Sitniewska E, Malyszko JS, Poniatowski B, Dobrzycki S. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in non-diabetic patients with stage 2-4 chronic kidney disease. Ren Fail 2008;30:1-4.

Malyszko J, Malyszko JS, Koc-Zorawska E, Kozminski P, Mysliwiec M. Neutrophil gelatinase-associated lipocalin in dialyzed patients is related to residual renal function, type of renal replacement therapy and inflammation. Kidney Blood Press Res 2009;32:464–9.

Jolanta Malyszko J, Ewelina Lukaszyk, Irena Glowinska I, Magdalena Durlik M. Biomarkers of delayed graft function as a form of acute kidney injury in kidney transplantation. Scientific Reports 2015;5:11684.

Published

01-06-2017

How to Cite

Al-shamma, Z. A., N. G. Alklyali, and I. Y. Alani. “SERUM NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) AS A PREDICTIVE BIOMARKER OF KIDNEY INJURY IN RENAL TRANSPLANTED PATIENTS and CHRONIC KIDNEY DISEASE”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 9, no. 6, June 2017, pp. 59-63, doi:10.22159/ijpps.2017v9i6.17510.

Issue

Section

Original Article(s)